CRC Research Update — August 02, 2026
Today's colorectal cancer research highlights
Curated CRC research — accessible, accurate, actionable
The CRC Digest
Sunday, August 02, 2026
IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.
CRC Research Update
-
REGULATORY
FDA Approves SimpleScreen CRC Blood-Based Screening TestThe FDA has approved SimpleScreen CRC, a new blood-based screening test for colorectal cancer, expanding non-invasive screening options. (The ASCO Post)
-
LIVING WITH CRC
Lean Body Mass Linked to Oxaliplatin Neuropathy RiskA study of colorectal cancer patients receiving adjuvant CAPOX found that lean body mass and sarcopenia may influence the risk of dose-limiting peripheral neuropathy, suggesting current body-surface-area dosing may not account for important individual differences. (Cancer Treatment and Research Communications)
-
TREATMENT
Surgery After Disease Progression May Still Benefit Select Liver Metastasis PatientsA Japanese nationwide study analyzed patients from the Colorectal Cancer Liver Metastasis Database who received chemotherapy. (Annals of Surgical Oncology)
-
TREATMENT
Liquid Biopsy Detects ctDNA in 95% of Metastatic CRC PatientsA Japanese single-center study using Guardant360 CDx found circulating tumor DNA in 18 of 19 metastatic colorectal cancer patients, with a median turnaround time of 11 days and pathogenic alterations identified in 79% of cases. (Journal of the Anus, Rectum and Colon)
Research continues to expand our understanding of how to personalize treatment and improve quality of life for the colorectal cancer community.
Get CRC research intelligence delivered weekly — free.
SubscribeCRC Digest
Not Medical Advice
The CRC Digest provides research summaries for informational and educational purposes only. This is not medical advice. Always consult your healthcare provider before making any decisions about your care.
Content is curated with AI assistance and reviewed by the editorial team.
Browse Past Issues · Read our full disclaimer · Manage subscription
Useful? Forward it to a colleague. Every topic in this briefing has a live research dossier — trajectory and evidence — at Signal Bureau.
Got this from a colleague? Subscribe here — we only ever add readers who sign themselves up.
Evolution Accelerator, Inc. (dba Evolution Labs) · 3941 Park Dr., Suite 20341, El Dorado Hills, CA 95762
You are receiving this because you subscribed to CRC Digest (self-serve signup)
Unsubscribe — honored promptly, no login required. · Privacy policy · Manage or delete your data